A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy Podcast By Annenberg Center for Health Sciences cover art

A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

By: Annenberg Center for Health Sciences
Listen for free

In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive care management.Annenberg Center for Health Sciences Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies

    Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies
    Jun 9 2022

    Large B-cell lymphomas (LBCLs) are one of the most common subtypes of non-Hodgkin lymphomas and while 1st-line standard of care has remained unchanged, the treatment paradigm has undergone a shift in recent years due to the development of novel therapeutic agents. These novel therapies include monoclonal antibody (mAb) therapies, mAb-conjugates, and chimeric antigen receptor (CAR)-T cell therapies.
    Show more Show less
    8 mins
  • Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies

    Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies
    Jun 9 2022

    Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies
    Show more Show less
    37 mins
  • Disease Burden and Overview of Large B-Cell Lymphomas

    Disease Burden and Overview of Large B-Cell Lymphomas
    Jun 9 2022

    B-cell lymphomas consist of a heterogenous group of lymphoproliferative neoplasms originating from B-lymphocytes.  
    Show more Show less
    4 mins
No reviews yet